EVEREST MED (01952) has announced its interim results for the six months ended June 30, 2026, with revenue reaching RMB 1.148 billion, a substantial 157.29% increase year-over-year.

Gross profit climbed 166.98% to RMB 799 million, while the loss attributable to equity holders narrowed dramatically by 97.62% to just RMB 5.944 million during the period.

The revenue surge was primarily driven by sustained robust sales growth of Nefecon, alongside service income generated under the commercialization services agreement with Haisco Pharmaceutical, the company explained.

To broaden its product portfolio, the company has enhanced utilization and productivity of its existing commercial platform while strengthening commercial capabilities and product lifecycle management. Gross margin improved to 69.6% for the six months ended June 30, 2026, up from 67.1% in the corresponding period of 2025, reflecting ongoing initiatives to boost supply chain efficiency and localize production.

The reduction in the six-month loss attributable to equity holders was mainly due to strong sales growth of the company's commercialized products, improved operational efficiency, and fair value gains from investments in financial assets related to Mecotef.

Key achievements during the reporting period include strong momentum in Nefecon's commercialization and real-world research progress, and Velsipity obtaining New Drug Application approval and commercial launch in mainland China.

The company also expanded its product pipeline through multiple licensing, acquisition, and collaboration agreements, and strengthened its Asia-Pacific commercialization platform by acquiring Haisco Pharmaceutical (Singapore). Additionally, it successfully completed the first out-licensing transaction for a product with global rights.

Multiple late-stage clinical development programs advanced, and the company's personalized mRNA tumor vaccine EVM16 released encouraging first-in-human clinical trial data.

These developments further solidify EVEREST MED's diversified product portfolio and enhance its commercialization and development footprint across the Asia-Pacific region, advancing the company toward its long-term strategic goal of becoming a leading biopharmaceutical company in the region.